Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 4 studies | 27% ± 7% | |
epithelial cell | 4 studies | 25% ± 9% | |
ciliated cell | 3 studies | 24% ± 10% | |
hepatocyte | 3 studies | 41% ± 14% | |
astrocyte | 3 studies | 31% ± 7% | |
glutamatergic neuron | 3 studies | 33% ± 12% | |
oligodendrocyte | 3 studies | 23% ± 5% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 4 studies | 31% ± 9% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 2987.24 | 1445 / 1445 | 100% | 22.59 | 183 / 183 |
prostate | 100% | 4595.42 | 245 / 245 | 100% | 36.65 | 501 / 502 |
ovary | 100% | 4981.92 | 180 / 180 | 100% | 22.46 | 429 / 430 |
stomach | 100% | 2584.75 | 359 / 359 | 100% | 18.86 | 285 / 286 |
intestine | 100% | 3157.25 | 966 / 966 | 100% | 17.39 | 525 / 527 |
breast | 100% | 3929.03 | 459 / 459 | 99% | 25.14 | 1111 / 1118 |
bladder | 100% | 3761.14 | 21 / 21 | 99% | 17.01 | 500 / 504 |
lung | 100% | 3661.54 | 578 / 578 | 99% | 20.34 | 1145 / 1155 |
pancreas | 100% | 2523.47 | 328 / 328 | 98% | 13.36 | 175 / 178 |
thymus | 100% | 3808.16 | 653 / 653 | 98% | 16.86 | 594 / 605 |
skin | 100% | 2910.91 | 1809 / 1809 | 98% | 17.23 | 463 / 472 |
brain | 97% | 1573.47 | 2563 / 2642 | 99% | 15.26 | 700 / 705 |
uterus | 100% | 4132.26 | 170 / 170 | 96% | 16.60 | 442 / 459 |
kidney | 100% | 2382.46 | 89 / 89 | 94% | 11.86 | 848 / 901 |
liver | 100% | 4020.24 | 226 / 226 | 91% | 11.88 | 369 / 406 |
adrenal gland | 100% | 2091.70 | 258 / 258 | 90% | 11.23 | 206 / 230 |
adipose | 100% | 3058.39 | 1204 / 1204 | 0% | 0 | 0 / 0 |
spleen | 100% | 3760.55 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 6.93 | 1 / 1 |
blood vessel | 100% | 3078.97 | 1334 / 1335 | 0% | 0 | 0 / 0 |
muscle | 100% | 1690.61 | 801 / 803 | 0% | 0 | 0 / 0 |
heart | 99% | 1657.59 | 851 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 98% | 2670.33 | 911 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 98% | 11.89 | 78 / 80 |
tonsil | 0% | 0 | 0 / 0 | 96% | 20.63 | 43 / 45 |
lymph node | 0% | 0 | 0 / 0 | 93% | 17.31 | 27 / 29 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0061188 | Biological process | negative regulation of rDNA heterochromatin formation |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_0006482 | Biological process | protein demethylation |
GO_0006338 | Biological process | chromatin remodeling |
GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
GO_0045943 | Biological process | positive regulation of transcription by RNA polymerase I |
GO_0007420 | Biological process | brain development |
GO_0000082 | Biological process | G1/S transition of mitotic cell cycle |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0005730 | Cellular component | nucleolus |
GO_0005654 | Cellular component | nucleoplasm |
GO_0031965 | Cellular component | nuclear membrane |
GO_0005634 | Cellular component | nucleus |
GO_0035064 | Molecular function | methylated histone binding |
GO_0032454 | Molecular function | histone H3K9 demethylase activity |
GO_0003682 | Molecular function | chromatin binding |
GO_0016706 | Molecular function | 2-oxoglutarate-dependent dioxygenase activity |
GO_0140683 | Molecular function | histone H3K9me/H3K9me2 demethylase activity |
GO_0003712 | Molecular function | transcription coregulator activity |
GO_0051864 | Molecular function | histone H3K36 demethylase activity |
GO_0032452 | Molecular function | histone demethylase activity |
GO_0005506 | Molecular function | iron ion binding |
GO_0008270 | Molecular function | zinc ion binding |
GO_0035575 | Molecular function | histone H4K20 demethylase activity |
GO_0071558 | Molecular function | histone H3K27me2/H3K27me3 demethylase activity |
GO_0005515 | Molecular function | protein binding |
GO_0140680 | Molecular function | histone H3K36me/H3K36me2 demethylase activity |
Gene name | PHF8 |
Protein name | Histone lysine demethylase PHF8 (EC 1.14.11.27) (EC 1.14.11.65) (PHD finger protein 8) ([histone H3]-dimethyl-L-lysine(36) demethylase PHF8) ([histone H3]-dimethyl-L-lysine(9) demethylase PHF8) PHD finger protein 8 |
Synonyms | ZNF422 KIAA1111 |
Description | FUNCTION: Histone lysine demethylase with selectivity for the di- and monomethyl states that plays a key role cell cycle progression, rDNA transcription and brain development. Demethylates mono- and dimethylated histone H3 'Lys-9' residue (H3K9Me1 and H3K9Me2), dimethylated H3 'Lys-27' (H3K27Me2) and monomethylated histone H4 'Lys-20' residue (H4K20Me1). Acts as a transcription activator as H3K9Me1, H3K9Me2, H3K27Me2 and H4K20Me1 are epigenetic repressive marks. Involved in cell cycle progression by being required to control G1-S transition. Acts as a coactivator of rDNA transcription, by activating polymerase I (pol I) mediated transcription of rRNA genes. Required for brain development, probably by regulating expression of neuron-specific genes. Only has activity toward H4K20Me1 when nucleosome is used as a substrate and when not histone octamer is used as substrate. May also have weak activity toward dimethylated H3 'Lys-36' (H3K36Me2), however, the relevance of this result remains unsure in vivo. Specifically binds trimethylated 'Lys-4' of histone H3 (H3K4me3), affecting histone demethylase specificity: has weak activity toward H3K9Me2 in absence of H3K4me3, while it has high activity toward H3K9me2 when binding H3K4me3. Positively modulates transcription of histone demethylase KDM5C, acting synergistically with transcription factor ARX; synergy may be related to enrichment of histone H3K4me3 in regulatory elements. . |
Accessions | ENST00000453905.5 H0Y7M8 ENST00000396282.7 ENST00000433120.5 H0Y589 B0QZZ3 ENST00000357988.9 [Q9UPP1-1] H0Y3N9 A0A8J8YW94 B0QZZ2 ENST00000443302.5 ENST00000448003.1 Q5JPR8 Q9UPP1 ENST00000338946.11 B0QZZ4 ENST00000445025.1 ENST00000687764.1 ENST00000415025.5 B0QZE1 ENST00000425862.5 A0A8I5KT77 A0A8I5KVK1 ENST00000437224.5 ENST00000322659.12 [Q9UPP1-5] ENST00000338154.11 [Q9UPP1-2] ENST00000686349.1 |